INTRODUCTION
Tumor ablation is broadly defined as the destruction of focal tumors by direct application of chemicals or energy. 1 Tumor ablation therapies are delivered via needlelike applicators and can be broadly categorized into systems based on chemical (primarily ethanol and acetic acid) and thermal or nonthermal energy. The most widely applied thermal ablation modalities in the liver include radiofrequency (RF), microwave (MW), laser, cryoablation, and highintensity focused ultrasonography (US). Irreversible electroporation (IRE) is generally classified as a nonthermal ablative modality, although cytotoxic temperatures can be achieved with IRE depending on the parameters used during treatment. [2] [3] [4] Tumor ablation in the liver has evolved to become a well-accepted tool in the management of increasingly complex oncologic patients. Ablative therapies can be used alone, in conjunction with other ablative therapies, or in combination with other oncologic treatment strategies, such as surgery, neoadjuvant and adjuvant chemotherapy, external beam and stereotactic body radiotherapy (SBRT), and arterial liver-directed therapies, including bland embolization, chemoembolization, and/or radioembolization in the treatment of both primary and secondary hepatic malignancies. [5] [6] [7] [8] [9] This image-rich, case-based article introduces some of the considerations that are important for physicians preparing to perform hepatic tumor ablation.
Ablation Modalities
The physical properties of each of the ablation devices are unique and these differences can affect the technical success of ablation procedures. Although an in-depth understanding of the biophysics of each device is not necessary, it is important to understand the properties of the devices available to your practice. Because operator experience has been correlated with success, it may be beneficial to concentrate experience in a few selected devices rather than dilute experience across multiple technologies. 10, 11 Ethanol Chemical (nonenergy) ablation with ethanol was the seminal technique for percutaneous ablation. Ethanol induces coagulative necrosis via protein denaturation, cellular dehydration, and chemical occlusion of small tumor vessels. Ethanol injection is well suited for small hepatocellular carcinoma (HCC) because the firm cirrhotic liver surrounding the soft tumor limits diffusion of ethanol into the surrounding liver. Ethanol injection has little utility in the treatment of metastases in which the background liver is normal. Because of the high rate of local tumor progression and the need for repeated treatments, ethanol has largely been replaced with thermal ablation (RF and MW), for which rates of local tumor control and survival have improved. [12] [13] [14] [15] [16] [17] [18] [19] [20] Chemical ablation has been used to augment or replace thermal ablation when treating tumors in areas of high perfusion-mediated tissue cooling or tumors in proximity to vulnerable, nontargeted structures, such as bile ducts (Fig. 1) . 21 
Fig. 1. (A)
Metastatic neuroendocrine tumor (NET) in the ventral right liver (arrow) abutting the bile duct draining Couinaud segment VIII (arrowhead). Given prior left hepatectomy and palliative intent of ablation, avoiding a bile duct stricture and further liver volume loss was a priority. (B) US and unenhanced computed tomography (CT) images during ethanol ablation. The posterior aspect of the tumor (arrow), in proximity to the bile duct, was targeted and 4 mL of 95% ethanol was instilled (arrowheads). (C) Unenhanced CT and US images after placement of the MW antenna (arrowhead) along the anterior aspect of the tumor. When the gas clouds (arrow) became confluent the procedure was terminated. (D) MR imaging obtained 1 month after combined ethanol and MW ablation. The ablation encompasses the index lesion (arrow) and there is no bile duct stricture (arrowhead). Because a 1-cm circumferential margin could not be safely obtained, there is a substantial risk for local tumor progress (LTP).
Radiofrequency
RF is a heat-based ablation method that creates zones of coagulative necrosis through the application of heat. With RF, an alternating current is conducted through an applicator (electrode) that acts as the cathode of a closed electrical circuit with grounding pads applied to the skin acting as the anode. Ions close to the electrode vibrate rapidly as they attempt to align with the alternating current, resulting in resistive tissue heating (direct heating) that is conducted into adjacent tissues (indirect heating) as a result of the high thermal gradient. [22] [23] [24] The final ablation is the result of both direct heating caused by the applied energy, and indirect heating, the result of thermal diffusion into adjacent, cooler tissues. RF is a self-limited process that has limited success in treating large tumors and tumors in regions of high tissue perfusion because of poor conductive heating and limited ability to overcome perfusion-mediated tissue cooling. [23] [24] [25] [26] [27] [28] [29] As a result, RF leads to an undesirably high rate of local tumor progress (LTP) in larger tumors (Figs. 2 and 3 ).
30-32
Microwave MWs use dielectric hysteresis to produce heat, resulting in coagulative necrosis, and are capable of penetrating tissues that are poor electrical conduits, such as lung, bone, and areas of desiccation/char. Water molecules are forced to align with an oscillating electric field emitted from an antenna, creating kinetic energy that is converted to heat. This method allows direct heating of a volume of tissue around the antenna with less reliance on conductive heating. 25 MW ablation is performed at either 915 MHz or 2.45 GHz.
Compared with RF, MW has more power and can produce larger and hotter ablations. Combined Liver Ablation with the ability to continuously power multiple antennas simultaneously, MW has improved capacity to overcome perfusion-mediated tissue cooling associated with large vessels (>2 mm) (see Fig. 3 ; Fig. 4) . [33] [34] [35] However, this increased power can result in vascular thrombosis of the portal vein, particularly in cirrhotic patients in whom portal venous flow rate is reduced (Fig. 5) . 36 Flow velocity within the inferior vena cava (IVC), hepatic arteries, and major hepatic veins is usually sufficient to prevent significant vascular thrombosis (see Figs. 3  and 4) . 37 MWs generate abundant water vapor, created by tissue out-gassing, which is well seen at both US and computed tomography (CT) (Figs.
6-8).
This gas cloud seen at US correlates with the size of the ablation zone at immediate postprocedure contrast-enhanced CT and the zone of necrosis at pathology in an animal model (see Figs. 6 and 8).
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Cryoablation
Modern cryoablation equipment uses the JouleThomson principle of thermodynamics. Highpressure argon is forced down a narrow tube within an insulated, hollow cryoprobe; near the tip of the cryoprobe the argon escapes the tube via a small aperture into an expansion chamber, resulting in rapid cooling and formation of an ice ball. When high-pressure helium is forced down the cylinder and allowed to expand within the hollow cryoprobe, the result is rapid heating and subsequent thawing of the ice ball. This combination of rapid cooling followed by thawing brings about the cascade of events leading to cell death that direct cellular injury by formation of intracellular ice crystals and interruption of cellular metabolism and ischemia from vascular thrombosis, resulting in coagulative necrosis and apoptosis.
During cryoablation, the ice ball is readily visible at imaging, allowing assessment of adequacy of ablation and risk to nontargeted anatomy (Fig. 9) . However, defining the lethal (À20 C and colder) isotherm within the visible ice, which can vary in distance from the ice edge depending on local factors, is not possible with imaging. 31, 39 A single cryoprobe ablation creates a very low volume of lethal ice because of perfusion-mediated tissue warming and should not be performed. 40 Multiple cryoprobes can be simultaneously powered to create large ablations; however, this has been associated with an increase in both hepatic and extrahepatic complications, including fracture of the liver, hemorrhage, and a systemic inflammatory response (cryoshock) that can lead to thrombocytopenia and coagulopathy, liver failure, acute lung, and kidney injury. These risks may be exacerbated in patients with baseline coagulopathy, and are most frequently reported in patients with cirrhosis. [41] [42] [43] [44] [45] [46] [47] [48] [49] Because cryoablation is associated with minimal pain, it is a viable treatment option for patients who are not candidates for general anesthesia or conscious sedation.
Irreversible electroporation
Irreversible electroporation, the only nonthermal energy-based ablative technology to date, delivers short bursts of high-voltage electrical pulses between closely approximated electrodes that create nanometer-scale pores in cell membranes, resulting in cell death. 3, 4 Depending on the voltage and duration of electric pulses, very high temperatures (>60 C) can be achieved, resulting in coagulative necrosis. 2 Because the predominant, nonthermal mechanism of cell death allows preservation of the extracellular tissue architecture, IRE has a theoretic advantage over thermal ablation, particularly in proximity to at-risk structures such as the biliary tree (Fig. 10) . 4 In the liver, experience with IRE remains limited and there are no comparison studies with thermal ablation that show equivalent efficacy.
Irreversible electroporation is technically challenging because precise and parallel electrode placement, required to maintain the electric field, is time consuming, generally requires more applicators relative to thermal ablation and requires the use of CT guidance for applicator placement. General anesthesia with a paralytic and cardiac synchronization is required, otherwise muscle spasms and cardiac dysrhythmias can occur.
INDICATIONS AND PATIENT SELECTION Hepatocellular Carcinoma
HCC is the most common primary liver cancer, the fourth most common type of cancer overall, At US, the HCC is hypoechoic (arrow). The MW antenna is well seen at both US and CT (arrowhead). (C) Artificial ascites was used to displace the stomach and pancreas; a trocar needle was placed through the left liver and a 2% iohexol-enhanced saline solution was infused (arrowheads). At CT, the stomach wall and pancreas were adequately displaced. The gas cloud at US (arrow) encompasses the HCC including a margin. (D) Enhanced CT in the late arterial (axial) and portal venous phase (coronal reformat) immediately after MW ablation. The ablation encompasses the index lesion including a 5 mm margin (arrow) without damage to the stomach or pancreas. The stomach and pancreas remained safely displaced (arrowhead) throughout the procedure and were not injured (arrowhead). and the third most common cause of cancer death worldwide. 50 There are substantial variations in the epidemiology of HCC; globally, the burden of disease is related to hepatitis B virus (HBV) and is largely concentrated in developing countries. In countries where HBV is not endemic, hepatitis C and alcoholic cirrhosis remain the most common risk factors. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis are other important risk factors for cirrhosis and HCC, particularly in developed countries. 51 In recent years the increased use of surveillance and improved diagnostic and therapeutic modalities have improved patient survival. [52] [53] [54] Liver transplantation remains the definitive treatment of patients with both cirrhosis and HCC; however, most patients never receive transplantation because of a lack of organ availability, lack of access to a transplant center, or inability to meet transplant criteria. RF ablation is considered the reference standard for the ablation of small HCC. Recently, newer generation high-powered MW (915 kHz-2.45 GHz) ablation has emerged as an alternative to RF. Compared with RF, MW systems generate higher tissue temperatures more quickly, and generally create larger ablations that are less susceptible to tissue perfusion from large (>2 mm) vessels. [33] [34] [35] Available evidence to date suggests that MW is at least equivalent to RF for the treatment of very early or early stage HCC. [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] RF ablation has been shown to be as effective as surgical resection for very early and early HCC.
68,69 However, it is important to understand that patient characteristics (eg, obesity and portal hypertension) and tumor location (eg, subcapsular location; proximity to the biliary tree, colon, or diaphragm) can influence image-guided ablation results and the occurrence of complications (see Fig. 5 ; Fig. 11 ).
70-73 In general, heat-based ablation, either RF or MW, should be considered first-line treatment of patients with liver dysfunction who have very early (stage 0) and early (stage A) HCC in favorable locations.
Other ablation devices, such as cryoablation, laser, focused US (high-intensity focused ultrasound [HIFU]), and IRE have been successfully used in the treatment of HCC. Compared with the reference standard (RF), cryoablation is associated with a higher rate of morbidity and mortality. In some studies, the major complication rate for cryoablation exceeds 6% (compared with a major complication rate for RF that is <1%). 49, 67, 70, 74 Major complications of cryoablation include cryoshock, hemorrhage, and liver failure. Laser and HIFU are other heat-based ablation devices that result in coagulative necrosis, similar to RF and MW. From a user standpoint, HIFU and IRE are more technically challenging than RF and MW. In addition, there are limited longitudinal data to accurately determine treatment response and equivalency of these modalities compared with RF.
Combination therapies
Exploiting synergies is the underlying principle for combination therapies. The most widely investigated combinations have been ethanol and RF, and TACE and RF. 6, 7, [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] Ethanol causes coagulative necrosis and thrombosis of tumor vessels, subsequently modifying local tissue perfusion. Chemotherapy combined with embolic particles in TACE induces ischemic necrosis and modifies local tissue perfusion. Ablations with both RF and MW are larger after ethanol and TACE because of decreased perfusion-mediated tissue cooling.
93-100
Hepatic artery embolization (HAE) therapies such as conventional TACE (cTACE) or TACE with drug-eluding beads (DEB-TACE) combined with ablation seem to improve technical success and decrease the incidence of LTP in select situations.
84,91,101,102 For HCCs larger than 3 cm, those that are poorly encapsulated, or those that have visible satellite tumors, combination therapy should be considered. In addition, HCCs that are in poor anatomic locations, such as Couinaud segment VII and VIII or immediately adjacent to a large vessel (>2 mm), or HCC that are inconspicuous at US, may also be good candidates for combination therapy (see Fig. 1 ). Both RF and MW ablation have been shown to be effective in the treatment of HCC after TACE.
83
There is no consensus on the optimal timing for intra-arterial therapies and ablation when used in combination. As a result, practice patterns vary widely, with ablation being performed both before and after HAE. The rationale for performing ablation before HAE is the augmented delivery of embolic particles into the hyperemic parenchyma surrounding the ablation, thereby increasing the treatment effect on the heatdamaged cells at the ablative margin; the most common location for LTP. 103 The rationale for performing ablation after HAE is to reduce perfusion-mediated tissue cooling and exploit a chemotherapy-heat synergy. Another reason to perform HAE before ablation is to aid in tumor targeting when CT is used for guidance and when tumors are inconspicuous at US. If ablation is performed after TACE, it is important to treat the entire tumor in addition to at least a 5-mm circumferential margin (Figs. 12-15 ). This technique is well tolerated and has been shown to decrease the incidence of LTP.
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Colorectal Cancer Hepatic Metastasis
Colorectal carcinoma (CRC) is the third most common cancer and the second most common cause of cancer-related mortality in the United States.
105
Metastatic disease is present at diagnosis of CRC in 20% and another 30% to 50% develop liver metastasis (colorectal liver metastasis [CRLM]) during treatment. Of those patients with metastatic disease, 25% to 30% have isolated hepatic metastasis. 106 Without treatment, median survival with CRC hepatic metastasis is 6.9 months, with a 5-year survival of 0%. 107, 108 Complete surgical resection confers the best chance for long-term survival; however, only 20% of patients with CRLM are candidates for resection. More effective neoadjuvant chemotherapy regimens and improved surgical techniques have had a significant impact on survival. At present, 5-year survival after hepatic resection for CRLM approaches 50%. 109, 110 In comparison, patients with CRLM treated with chemotherapy, but who do not undergo liver resection have a 5-year overall survival (OS) of 10%. 111 Although OS has improved, approximately 45% of patients experience early recurrence (within 6 months) after liver resection, whereas 75% experience recurrent disease overall. Early recurrence negatively affects prognosis, with an approximately 50% reduction in 5-year OS compared with late recurrence. With repeat resection, OS for early recurrence is similar to patients reresected for late recurrence. 112 Risk factors for recurrence include T3-T4 primary tumor, synchronous liver metastasis, more than 3 liver metastases, largest liver metastasis greater than 5 cm, and a 0-mm resection margin. 112, 113 Response to neoadjuvant chemotherapy and administration of adjuvant chemotherapy reduce early surgical recurrence. 112 Adjuvant chemotherapy has not been shown to improve OS; however, is still used because of improvement in progression-free survival (PFS). [114] [115] [116] [117] A phase II randomized controlled trial comparing systemic therapy alone with RF ablation and adjuvant chemotherapy for CRLM showed improved PFS with adjuvant chemotherapy. 118 
Ablation
The role of percutaneous ablation in the management of CRLM remains in debate; however, ablation is widely accepted for patients with unresectable tumors, those who are not surgical candidates, and in the setting of recurrent disease after liver resection when insufficient liver reserve precludes further resection. Although retrospective studies have concluded that resection offers better survival than ablation, no randomized controlled trials have been performed to date. Of the studies comparing surgical resection and ablation, patient selection favors surgical resection in virtually all cases. 119, 120 Patients in the ablation arm tend to have a greater burden of disease, a higher rate of extrahepatic tumors, and larger tumors, tend to be older, and tend to have more comorbidities. In those studies in which ablation has been used as first-line therapy for patients with resectable CRLM, the 5-year survivals are similar to those of surgical series. 121, 122 Other retrospective studies show comparable survival with surgical series when ablation is applied to CRLM less than 3 cm. [123] [124] [125] [126] Small and medium-sized CRLM are suitable for percutaneous ablation, with the most Fig. 16 ). Depending on the location of the tumor and the technology, tumors of up to 5 cm can be successfully treated with an acceptable rate of LTP. 121, [127] [128] [129] [130] Multiple ablations in a single session or repeat ablation can safely be performed for limited disease when there is sufficient hepatic reserve (see Fig. 16 ). As with surgical resection, the best results following liver ablation for CRLM are achieved in the setting of a solitary tumor less than 3 cm. 123, 131 Compared with resection, LTP is more common following ablation and the risk increases for larger tumors. 121, [127] [128] [129] [130] 132 However, these differing rates of LTP have not had an apparent effect on OS. 122, 124 One possible explanation for this dichotomy between LTP and OS between patients after ablation and resection may be that patients who have experienced LTP and/or distant intrahepatic tumor progression after ablation are often candidates to undergo repeat ablation (or resection) because ablation spares more healthy liver tissue relative to surgery. 
Neuroendocrine Cancer Hepatic Metastasis
Neuroendocrine tumors (NETs) are a diverse group of malignancies with variable, although often indolent, biological behavior. Clinical behavior and prognosis correlate closely with histologic differentiation and World Health Organization (WHO) grade. For patients with low-grade (G1) or intermediate-grade (G2) histology and metastatic disease, survival is highly variable and can depend on factors unrelated to histology, such as primary tumor location. For example, survival in the setting of advanced carcinoid disease is much worse for patients with the primary tumor arising from the colon and lung (median OS, 7 and 17 months respectively) compared with the small bowel (median OS, 55-65 months). As a result, assessment of comparative benefit among treatment strategies is difficult, given the various natural histories of these malignancies. 133 Most patients with advanced NET have hepatic metastatic disease. Management of these patients is complex and requires a multidisciplinary team approach, with consideration of age, performance status, clinical symptoms, extent, and biology of disease. Surgical resection provides clear benefit with symptom palliation and favorable long-term survival. [134] [135] [136] [137] [138] However, progressive hepatic metastatic disease and recurrent symptoms occur in 85% to 95% of patients. In the setting of limited, isolated liver hepatic metastatic disease, orthotopic liver transplantation (OLT) has been attempted; however, the role of OLT in metastatic NET is not yet established and remains controversial. Clinical symptoms depend on a variety of factors, including the site of the primary tumor; the presence of synchronous and metachronous tumors; and the extent and location of local, regional, and distant metastasis. Clinical syndromes are the result of hormone hypersecretion from gastropancreatic NETs or release of vasoactive substances (serotonin) into the systemic circulation from hepatic metastasis. Somatostatin analogues (octreotide or lanreotide) and cytotoxic chemotherapies are useful in controlling both tumor growth and hormone-related symptoms in advanced metastatic disease. 133 Most patients present with multifocal, bilobar metastatic disease and thus are not surgical candidates and are unlikely to benefit from percutaneous ablation. HAE, alone or as an adjunct to medical therapy, has been a successful palliative technique for patients with liver predominant disease with response rates, as measured by decreased hormone secretion, symptom benefit, and/or radiologic response, generally exceeding 50%. Similar tumor response rates, symptom palliation, and survival have been shown among bland embolization, chemoembolization (cTACE and DEB-TACE), and SIRT. [144] [145] [146] [147] [148] [149] [150] [151] [152] Thus, appropriate patient selection is an important consideration to minimize treatment-related side effects among the HAE treatment options.
Ablation
The role of ablation in the management of NET liver metastasis remains undefined, although it is largely accepted as a palliative treatment option in nonsurgical candidates and as an adjunct to surgical resection in patients with oligometastatic disease (see Fig. 1 ). Patients who undergo resection almost always develop new sites of metastatic disease in the liver remnant. Because repeat liver resection may not be feasible because of limited hepatic reserve, percutaneous ablation, in combination with chemotherapy and somatostatin analogues, can provide relief of clinical syndromes and prolong OS. 137, 153 Consensus-based guidelines put forth by the National Comprehensive Cancer Network recommend cytoreductive surgery and/or ablation if near-complete eradication of hepatic tumor burden can be achieved.
Most published reports of tumor ablation are small (<40 patients) retrospective case studies. The largest series included 89 patients with hepatic metastatic NET treated with laparoscopic RF. 153 In this cohort, a mean of 6 lesions (and up to 16 lesions) were treated in a single session; most patients (73%) had durable (median, 14 months) symptom relief.
Other Hepatic Tumors
For other hepatic malignancies, either primary or secondary, it is important to understand the underlying disease process and tumor biology. For example, performing tumor ablation if there is rapidly progressing metastatic disease or extensive extrahepatic metastatic disease is unlikely to be beneficial. However, patients with oligometastatic disease who have had a durable response to adjuvant therapies may benefit from liver tumor ablation. 118 The size, location, and number of hepatic tumors and the extent and location of extrahepatic metastases are important considerations.
Breast Cancer Hepatic Metastasis
Breast cancer is the most common malignancy and the leading cause of cancer-related mortality in women. 154 The prognosis remains poor for metastatic breast cancer despite the introduction of modern chemotherapeutic regimens and biologics, with a median OS of 24 to 30 months and a 5-year survival of 23%. 155, 156 Both synchronous and metachronous hepatic metastases occur, and usually signify metastatic disease elsewhere; most commonly the lung, bone, nodes, and brain. 157 Isolated hepatic metastasis is uncommon but still portends a poor prognosis, with median OS of approximately 12 months and 5-year survival of 8.5%. 155, 158, 159 Prognosis has been linked to human epidermal growth factor receptor 2 (HER2) expression in liver metastasis, presence of extrahepatic metastasis, and patient age. 160 Breast cancer hepatic metastases have typically been treated with chemotherapeutics alone, with surgery reserved for palliation in symptomatic patients. 161 However, more recently several small retrospective series suggest a survival benefit in carefully selected patients even if there is extrahepatic disease. 160, [162] [163] [164] Alone or combined with surgery, thermal ablation may improve survival. In a small case series of 50 patients, RF ablation of limited hepatic metastatic disease in the setting of stable or limited extrahepatic metastatic disease improved median OS to 43 months (see Fig. 3 ).
160,165
Benign Hepatic Tumors Arguably, patients with benign hepatic tumors are the ideal candidates for percutaneous tumor ablation. Because the underlying disorder is benign, complete ablation may not be necessary and there is a wide window of opportunity to obtain a complete ablation, if needed. However, the treatment alternatives generally offered are surgical and are associated with significant morbidity. Thus, a minimally invasive alternative is extremely appealing for these often young and otherwise healthy patients.
There are a variety of benign liver tumors that can be treated, including simple and complex cysts, focal nodular hyperplasia, and hemangiomas and adenomas. Liver cysts and hemangiomas are generally small, follow an indolent course, and require no specific imaging or follow-up. In contrast, adenomas can rupture or infrequently undergo malignant transformation.
Hemangiomas can become large; cause mass effect on local structures, such as the central bile duct, stomach, or duodenum; or stretch the Glisson capsule, resulting in obstructive symptoms, anorexia, weight loss, and abdominal pain. Although surgical resection has been the historic standard of care in symptomatic patients, percutaneous ablation provides a much less invasive option with lower morbidity. Because hemangiomas are benign, complete ablation is not necessary and should be avoided when critical structures, such as central bile ducts, are at risk (Fig. 17) . There are a few small case series using RF or MW to treat hemangiomas with high technical success, low morbidity, and durable symptom relief. [166] [167] [168] [169] [170] [171] Hepatic adenomas are rare; typically arise in women using oral contraception; and infrequently occur in men, in whom they can be associated with anabolic steroid use. Glycogen storage diseases (type I and III) are associated with multiple adenomas. 172 Compared with other benign tumors, management is more complex because of the risk of hemorrhage and malignant transformation. Active surveillance, surgical resection, embolization, and ablation have all been used. Adenomas larger than 5 cm, those that fail to regress or that grow despite withdrawal of hormones, those that have beta-catenin activation or dysplasia/atypia at biopsy, and adenomas in men should be surgically resected or ablated. [172] [173] [174] Even though adenomas are benign, complete ablation should be achieved to avoid delayed complications, such as hemorrhage or malignant transformation (Fig. 18) .
ABLATION PROCEDURE AND SURVEILLANCE Local Tumor Progression
The liver surrounding a malignant liver tumor often contains satellites of carcinoma that are invisible at conventional imaging. These tumor satellites are frequently the cause for LTP in technically successful ablations (ie, ablations without imaging evidence of residual tumor on immediate or shortterm follow-up; see Fig. 16; Fig. 19 ). The extent and distance of the satellites from the index tumor are variable, and depend on factors such as tumor type, size, degree of differentiation, and vascularity. Therefore, the goal of tumor ablation is to encompass both the index tumor and a circumferential margin appropriate for the tumor type.
Ablative margin: hepatocellular carcinoma The size and degree of differentiation of HCC determine the presence and extent of satellite tumors. Hypervascular HCC is associated with capsular invasion and satellite tumors. As HCC progresses from well to poorly differentiated, the presence and size of satellites increases, and as the index tumor increases in size, the number of satellites increases. However, the size of the index HCC does not affect the distance of the satellite from the index HCC. For HCCs less than 2 cm and HCCs between 2 and 3 cm, the mean distance of the satellite from the index HCC was 5.3 and 4.8 mm, respectively. Nonhypervascular HCC (at CT angiogram) rarely has satellite tumors, regardless of size. 175 For HCCs less than 3 cm, a minimum of a 5-mm circumferential ablative margin must be achieved in order to maximize the odds of complete ablation and reduce the rate of LTP. [175] [176] [177] [178] [179] The overall ablation zone size can easily be underestimated for a particular tumor. For example, a 2-cm HCC should be treated with (at minimum) a 3-cm zone of ablation, provided that the tumor is centered within the ablation. If off center, the zone of ablation should be larger. If an HCC is near or abutting the liver capsule, the ablation should extend to the liver capsule. For HCCs larger than 3 cm, those that lack a capsule, or those that have gross satellites present on conventional imaging, combination therapy and/or larger circumferential margins may be necessary to achieve local tumor control. 180 Ablative Margin: Colorectal liver metastasis and other hepatic metastases The biology and perfusion of the tumor relative to the surrounding liver are important factors to consider when planning ablation of hepatic metastases. Relative to the adjacent liver, CRLMs are less well perfused than the surrounding liver. As a result, the index tumor is easier to ablate than the margin of normal liver. 181 Similarly, the water content of metastatic NET relative to adjacent liver parenchyma allows easier ablation of the mass compared with the liver margin. Nevertheless, a minimum of a 1-cm circumferential ablative margin must be achieved in order to maximize the odds of complete ablation and reduce the rate of LTP in CRLM. 132 For example, a 2-cm metastasis should receive (at minimum) a 4-cm zone of ablation, provided the index lesion is centered within the ablation. If off center, the zone of ablation should be larger. If a mass is within 1 cm of the liver capsule, the ablation should extend to the liver capsule. Obtaining at least a 1-cm margin in all directions is particularly important with ill-defined tumors. These tumors tend to have more satellite tumors at distances further from the index tumor.
182,183
Technique-specific Considerations Excellent preprocedure imaging, either with contrast-enhanced CT or MR imaging, is necessary for ablation planning. This imaging allows evaluation of the extent of disease within the liver and the proximity of the tumor to major vessels and nontargeted anatomy. When comparison imaging is available, interval change in burden of hepatic and extrahepatic disease can provide insight into tumor biology. For HCC, preprocedure imaging within 1 to 2 months is usually sufficient. However, the doubling rate of CRLM, among other hepatic metastases, is much shorter than that of HCC, so preprocedure imaging should be obtained within 2 weeks of ablation.
Anesthesia
Tumor ablation has been performed with general anesthesia (GA), conscious sedation, and local anesthesia with or without sedation. When combined with a paralytic, GA can render the diaphragm motionless, allowing precise applicator placement. The Valsalva technique can improve tumor conspicuity and access to tumors, particularly those in the dome of the liver. Continuous hemodynamic monitoring by anesthesiology and improved pain control are other advantages of GA.
Relative to GA, deep or conscious sedation reduces procedure time and time between patients and is not associated with the same risks as GA. However, shallow tidal volumes can limit tumor conspicuity, particularly for tumors near the dome, and respiratory motion can make applicator placement more challenging. The higher rate of LTP for subcapsular tumors treated under conscious sedation may be partially explained by the fear of inducing pain decreasing treatment time and/or power. 182 Expected duration of the ablation procedure, number of applicators to be placed, conspicuity of the tumor, expected ease of applicator placement, and the ability of the patient to remain in the preferred position are factors to consider when determining the need for GA.
Nontarget anatomy
A variety of techniques can be used before and/or during ablation to reduce the risk of collateral damage. Patient positioning, instillation of intraperitoneal fluid or gas, insufflation of intraperitoneal balloons, applying traction on applicators, biliary perfusion with chilled fluids, and intentional pneumothorax are techniques that have been used to protect nontargeted anatomy.
Patient positioning A supine position is convenient, safe, and can expedite the procedure. However, nontargeted structures, such as the lung and diaphragm, frequently preclude safe access to liver masses with CT, particularly those near the dome. Even though US provides a greater variety of access points into the liver for tumor ablation, a supine position is frequently suboptimal.
Oblique and lateral decubitus positions allow access to a greater number of hepatic tumors, particularly those near the dome of the liver. These positions can allow nontargeted anatomy to move. In addition, the operator may be able to optimize placement of the applicators so as to protect nontargeted structures while ensuring adequate coverage of the index tumor (see Figs. 6, 11, 12,  16, 18; Fig. 20 ).
Diaphragm Hepatic tumors in proximity to or abutting the liver capsule, particularly those near the dome of the liver, pose unique challenges. Conspicuity of these tumors at US can be suboptimal because of rib shadow, the lung edge, or poor acoustic penetration making applicator placement difficult. As a result, primary effectiveness is reduced, the rate of LTP is higher, and patients experience more postprocedure pain. [184] [185] [186] [187] [188] [189] Artificial ascites, directed toward the subdiaphragmatic space, can improve tumor conspicuity at US, reduce the rate of primary failure and LTP, and reduce postprocedural pain (see Figs. 6, 11, 12, 16, 18, 20) . [190] [191] [192] [193] [194] [195] [196] A transthoracic CT-guided approach to tumors near the dome of the liver, without or following the creation of an artificial pneumothorax or pleural effusion, has been described and can be safe and effective. The most commonly reported complications are pneumothorax and pleural effusion. 100, [197] [198] [199] Although seeding the pleural space with tumor is a concern, the incidence is likely extremely low and comparable with incidence of seeding the peritoneum. Central bile ducts Extending a zone of ablation to central bile ducts (right and left hepatic ducts, common hepatic and common bile ducts) can result in bile duct stricture and progressive loss of subtended liver parenchyma. 200 Bile leaks, cholangitis, and liver abscesses can subsequently occur, leading to significant morbidity. For patients with metastatic disease, these complications can delay initiation or reinstitution of chemotherapy, potentially resulting in decreased survival. Although high-flow bile duct cooling can be protective, ablation within 1 cm of a central bile duct should be avoided. 201, 202 Alternative therapies, such as IRE, ethanol ablation, HAE, and SBRT, should be considered when appropriate for a particular tumor type (see Figs. 1 and 17) .
Hepatic vasculature Complete ablation of tumors adjacent to high-flow blood vessels larger than 3 mm in diameter is challenging because of perfusion-mediated tissue cooling heat sink (see Fig. 2) . 23, 26, 27 Several strategies have been used to combat perfusion-mediated tissue cooling, including increasing power and time of ablations in proximity to major vasculature, targeted placement of applicators closer to vessels, and occlusion of hepatic vasculature with peripherally inserted balloon catheters (see Figs. 3 and 4) . From a technology perspective, high-powered MW is less susceptible to perfusion-mediated tissue cooling than RF, and IRE may be unaffected by perfusion-mediated cooling (see Figs. 3 and  4) . 34, 203 In contrast, patients with cirrhosis and slow portal venous flow are at increased risk for portal venous thrombosis (PVT) caused by heat transfer. 29, 37 PVT can increase portal vein pressure, leading to decreased liver function, worsening ascites, and increased risk for variceal bleeding. Because of the low incidence with RF and tendency to resolve, historically PVT has been of minimal concern. 204 With the higher temperatures and larger ablations of MW, the risk for PVT may be higher. 34 Anticoagulation therapy generally results in complete or nearcomplete resolution of PVT (see Fig. 5 ).
Image guidance
Many different tools have been used for imaging guidance, including US, CT, MR imaging, fluoroscopy, and more recently fused PET-CT following the administration of fluorine-18-fluorodeoxyglucose. 205 Each technique has strengths and limitations; the choice of guidance technique should be tailored to the unique situation for each patient. When technically feasible, US is an excellent guidance tool for applicator placement. The largest published series with the lowest LTP rates following percutaneous ablation almost invariably have used US guidance for applicator placement and ablation monitoring. 36, 128, 206 Ultrasound offers high soft tissue contrast, simultaneous assessment of the tumor and applicator, fixed guides to assist applicator placement, and the ability to interrogate flow within hepatic vasculature, among other advantages (see Figs. 1, 3, 4 , 6, 8, 14, 20) . However, US is operator dependent and its utility may be compromised by tumor location and body habitus.
CT as a guidance tool allows for evaluation of the entire liver and proximity of non-target anatomy; however, CT is limited by poor soft tissue contrast. Retained ethiodized oil, from prior HAE, can provide a target for CT guidance without compromising the ability to use US (see . Radiation exposure to the patient and operator is another disadvantage of CT guidance.
Other guidance techniques, such as MR imaging, PET-CT, and fused US/CT-MR imaging, have been used successfully as guidance tools for percutaneous ablation, but are not universally available. [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] MR imaging offers superior lesion characterization, relative to CT, and the ability to monitor index ablation temperatures (thermometry); however, not all ablation devices are MR imaging compatible. Small bore sizes can limit applicator placement at MR imaging, particularly in obese patients.
Multiple applicator synergy
Treating large tumors with adequate margins requires the creation of large ablation zones. There are 2 methods to achieve large heat-based ablations: multiple overlapping ablations with a single applicator repositioned to different locations (sequential) and multiple applicator (simultaneous) ablation. Sequential RF and MW ablations result in smaller, less predictable ablations with clefts, whereas simultaneous ablation creates larger, confluent, and more predictable ablations (see Figs. 3, 7, 9; Fig. 21) . 219, 220 There have been no clinical studies directly comparing sequential and simultaneous ablation techniques. However, sequential ablation has been shown to be an independent predictor of primary treatment failure with RF. 221 
Periprocedural monitoring
Monitoring ablations during treatment can facilitate complete ablation. 222 During chemical and thermal ablation, US, CT, and MR imaging can be used to observe the growing ablation and confirm that the tumor and margin are sufficiently covered (see Figs. 1, 6-9, 14, 16) . Evaluation of the ablation immediately following treatment with contrast-enhanced US, CT, or MR imaging is strongly recommended. If the tumor is inadequately treated, additional ablation should be performed at the same treatment session if possible (see Fig. 18 ).
POSTPROCEDURE SURVEILLANCE
There is no consensus on the optimal interval or frequency of postprocedure imaging. Because LTP is much more common in the first year, most investigators suggest that surveillance imaging in the first year should be more frequent. 223, 224 Besides imaging, tumor markers such as alpha-fetoprotein for HCC and carcinoembryonic antigen and/or carbohydrate antigen 19-9 for CRLM, can identify disease progression and provide prognostic information.
Both CT and MR imaging are useful tools in postablation surveillance, each with unique advantages. CT is less prone to artifact compared with MR imaging and has the advantage of complete evaluation of the thorax in the same session. However, contrast-enhanced MR imaging has much better soft tissue characterization, offering improved assessment of the index ablation and progression of hepatic disease. Both CT and MR imaging are useful in the assessment of extrahepatic abdominal metastatic disease. The addition of PET-CT to surveillance in CRLM or breast cancer hepatic metastases is useful in the setting of increasing tumor marker levels if there is negative, equivocal, or indeterminate anatomic imaging (see Fig. 16 ). As a general rule, the postablation imaging modality can be based on the modality that best evaluated the tumor on preablation imaging.
Multiphase postcontrast imaging to include late arterial, portal venous, and delayed (3-5 minutes) phases should be considered after tumor ablation for hypervascular tumors including HCC and NET (see Figs. 8 and 21 ). This technique allows evaluation for both local and regional tumor progression. Growing peripheral nodular enhancement at the ablation margin indicates LTP (see Figs. 16  and 19) . Dual-energy CT may improve detection of LTP because of improved definition of the ablation zone and higher lesion-to-liver contrast on the iodine map relative to standard blended images. Single-phase postcontrast CT (portal venous phase) is adequate for anatomic surveillance and restaging of CRLM and breast cancer hepatic metastases (see Figs. 2, 3, 9, 16 ). In addition to peripheral nodular enhancement, LTP can also present as enlargement of the index ablation.
With MR imaging, hepatobiliary contrast (gadoxetic acid) is particularly useful in restaging hepatic metastatic disease (see Fig. 1 ).
SUMMARY
Physicians performing ablation should be familiar with the ablation devices they use and the technical aspects of the procedure that can improve primary effectiveness and reduce complications. At present, percutaneous ablation is first-line therapy for very early and early HCC and second-line therapy for CRLM, and is a treatment option for other hepatic tumors on a case-by-case basis. An understanding of the underlying tumor biology is important when weighing the potential benefits of ablation. Achieving a circumferential ablative margin, at least a 0.5 cm for HCC and at least 1.0 cm for liver metastases, decreases LTP.
Surveillance imaging after ablation should be most frequent in the first year, when rates of LTP are the highest. 
